Skip to content
Study details
Enrolling now

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

UCB Biopharma SRL
NCT IDNCT04715646ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

70

Study length

about 9.3 years

Ages

0.0833333333333333+

Locations

2 sites in NC, NY

What this study is about

Researchers are testing the safety and tolerability of brivaracetam in children and adolescents with seizures. The trial will evaluate how well brivaracetam works over a long period of time.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Brivaracetam

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

brivaracetam

Drug routes

injection, intravenous

Endpoints

Primary: Incidence of treatment-emergent adverse events (TEAEs) during the study, Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug during the study, Incidence of treatment-emergent serious adverse events (SAEs) during the study

Body systems

Neurology